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Abstract 
A non-invasive view of the brain with the aid of 
magnetic resonance imaging (MRI) is invaluable for 
studying pathological processes during autoimmune 
encephalomyelitis. Several MRI technologies are available 
that can be employed to study inflammation within the 
brain. These include labeling of inflammatory cells with 
paramagnetic contrast agents (such as USPIO/SPIO/VSOP 
iron-oxide or perfluoro carbon (PFC)-rich nanoparticles) 
and new tools that facilitate high resolution imaging 
particularly MR microscopy (µMRI, microscopic MRI; 
MR histology). In this review we will go into both MRI 
technologies, with a special focus on their applicability in 
studying brain inflammation in the experimental 
autoimmune encephalomyelitis (EAE).  
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Regarding cell labeling we will focus on PFC 
nanoparticles and fluorine (19F) MRI since these have 
introduced a number of advantages over T2*-weighted 
MRI with paramagnetic iron-oxide nanoparticles. 
Another MRI technology that we will be discussing is 
high resolution µMRI with cryogenically-cooled RF 
coils. This technology will enable neuroscientists to 
achieve a comprehensive, detailed and non-invasive 
view of the brain within short acquisition times: an 
important practical consideration when conducting 
longitudinal studies on the kinetics and dynamics of 
immune cell infiltration into the brain.   
 
 
Introduction 
Inflammatory diseases of the central nervous system 
(CNS), such as multiple sclerosis (MS), involve a 
recruitment of immune cells during the early stages of 
pathogenesis, prior to the onset of clinical symptoms 
1,3. Normally the blood-brain barrier (BBB) restricts 
migration of immune cells to the CNS, but during 
inflammation its function becomes altered. Immune 
cells gain access to CNS parenchyma via a complex, 
multi-step process that involves crossing both the 
vascular endothelium and the glia limitans 4,5. The 
experimental autoimmune encephalomyelitis (EAE) is 
an animal model that has been invaluable to shed 
further light on mechanisms underlying CNS 
autoimmunity. Indeed, the EAE model has been 
widely employed to examine the basic biology of CNS 
inflammatory processes, and to evaluate the 
effectiveness of nascent therapeutic approaches for 
MS 6,11. The pathology of EAE – that is brought about 
via subcutaneous injection of myelin antigen (eg. PLP, 
myelin proteolipid protein; MOG, myelin 
oligodendrocyte glycoprotein; MBP, myelin basic 
protein) – varies between different animal species 12. 
In mice (depending on the genetic background) 
pathology usually develops 1–2 weeks following 
immunization with myelin antigen. Lymphocytes 
(including antigen-specific T cells and B cells) and 
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antigen presenting cells (APC) accumulate mostly in the 
spinal cord but also in the cerebellum and less commonly 
in the cerebral cortex 13,14. The pathology is in fact 
characterized by an ascending paralysis, commencing at 
the tail and moving rostrally to affect hind limbs and 
ultimately the forelimbs 15,16.  
 
Figure 1. Current view of immune cell infiltration during 
autoimmune encephalomyelitis.  
The invasion of myelin-specific T cells into the CNS occurs in 
two phases. The first wave of immune-cell entry involves the 
passage of a first group of surveying myelin-specific T cells 
through the blood–CSF barrier (BCB) into the non-inflamed 
brain. The second wave of immune-cell entry involves an 
activation of the blood–brain barrier (BBB) and transmigration 
of myelin-specific T cells into the CNS parenchyma via the 
BBB following reactivation by myelin-loaded antigen-
presenting cells (APC) in the perivascular spaces (or Virchow 
Robin Spaces, VRS) 
 
 
Pathophysiology of neuroinflammation 
EAE studies focusing on the early stages of brain 
inflammation have revealed new insights on the 
mechanisms involved in the different waves of immune 
cell entry during evolution of CNS autoimmunity 17. The 
current paradigm is that the invasion of myelin-specific T 
cells into the CNS occurs in two phases (Figure 1). The 
first wave of immune-cell entry involves a chemokine-
dependent passage of a first group of patrolling myelin-
specific T cells through the blood–CSF barrier (BCB) into 
the non-inflamed brain 10. These cells cross the choroid-
plexus blood vessels accessing the choroid tissue stroma 
and then migrate through the tight junctions between the 
chemokine-rich ependymal cells to enter the cerebral 
ventricles, from which they migrate to the 
subarachnoid space.  
The second wave of immune-cell entry involves an 
expansion of myelin-specific T cells in the 
perivascular spaces and activation of the blood–brain 
barrier (BBB). The activated BBB that expresses 
increased amounts of adhesion molecules promotes the 
rolling, tethering and crawling of T cells to the inner 
wall of activated cerebral blood vessels (usually 
against the blood flow) to cross into the subarachnoid 
space, where they are presented with specific antigen 
by local resident antigen-presenting cells 11. Following 
restimulation, myelin-specific T cells produce large 
quantities of cytokines and enter the CNS parenchyma 
– following a disruption of the BBB – to initiate the 
destructive chain of events in the brain tissue. 
To gain a comprehensive and longitudinal view of 
brain inflammation – particularly during the early 
stages of EAE – methods employing high resolution 
brain imaging would be advantageous. In MS patients 
the detection of contrast-enhancing lesions (CEL) by 
Magnetic Resonance Imaging (MRI) at the site of 
BBB disruption as a result of contrast agent leakage 
into the CNS parenchyma has been used for several 
years as a correlate of active inflammation 18,19. 
However, this does not provide direct evidence of 
immune cell trafficking into the CNS 20,21, and may 
occur independently of the formation of new lesions 22. 
There is therefore a need to pursue supplemental MRI 
techniques, to gain a more accurate and 
comprehensive view of the pathogenesis of CNS 
inflammation.  
 
Boosting the effective spatial resolution 
Scientists performing MRI on small animals are 
faced with one common dilemma: to observe sufficient 
detail in anatomical structures analogous to those in 
the human brain. There has been indeed an intense 
effort to maximize the effective spatial resolution of 
the MR images, beyond that required by clinical MRI. 
Microscopic MRI (µMRI or MR histology) – 
defined as MRI with a spatial resolution <100 μm 23,24 
– is one means of amplifying image detail in order to 
observe even minor changes in brain pathology during 
the course of disease. MRI resolution depends on 
several factors including magnetic field strength, 
gradient strengths and digital resolution, but the main 
limiting factors are coil sensitivity and signal-to-noise 
ratio (SNR) 25. Upon reducing voxel size to amplify 
spatial resolution, a loss in SNR is to be expected. This 
loss can be considerably compensated for by 
increasing signal averaging: this produces images with 
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an impressive level of microscopic detail as shown in ex 
vivo fixed brain tissue samples 26. However, increased 
signal averaging comes at a cost in scan time, and is hence 
not practical for studies with anesthetized animals. This 
along with the presence of movement artifacts makes it 
inherently difficult to achieve sufficient resolution to 
visualize brain pathology in vivo.    
 
 
Figure 2. Horizontal T2-weighted (T2W) image of a healthy 
mouse brain.   
A TurboRARE MRI sequence (TR/TE 3000/36ms; 47 µm2 in 
plane resolution, 16 slices of 400µm thickness) provides good 
contrast between grey and white matter boundaries (especially 
in the cerebellum). These horizontal scans that cover the entire 
mouse brain were perfumed in 5 minutes and delineate the 
three cortical layers of the cerebellum (ml, molecular layer; pl, 
Purkinje cell layer; gl, granular cell layer) surrounding the 
white matter (wm) of the arbor vitae. 
 
Our group is employing a method that uses 
cryogenically-cooled RF detection devices on a 9.4-
Tesla animal MRI to increase signal-to-noise ratio 
(SNR) and maximize effective spatial resolution in 
mouse brains 27. The RF coils used are made of 
superconducting material that helps reduce coil 
resistance and thermal noise and therefore increase 
SNR by up to a factor of 2.9 28. This system increases 
the virtual field strength by a factor of at least 2 (circa 
19 Tesla) without the disadvantages associated with 
higher field strengths, such as stronger susceptibility 
artifacts and B0 inhomogeneities. We performed high 
spatial resolution µMRI of mice brain during the 
course of EAE in an attempt to visualize early 
inflammatory pathology in vivo prior to and during 
commencement of disease. The quality of the images 
achieved with these RF coils is depicted in Figure 2. 
Our ultimate aim is to employ µMRI to follow the 
evolution of lesions in longitudinal studies. We have 
demonstrated that brain pathology can be detected 
prior to disease manifestation – even without the use 
of contrast agents – and showed excellent 
correspondence between µMRI findings and 
conventional histology (unpublished observations). 
 
Non-invasive tracking of different cell 
populations  
As mentioned in the previous section, the main 
strength of µMRI in studying brain autoimmunity is 
that it gives the opportunity to follow the lesion 
evolution non-invasively over the course of disease. 
However to gain a comprehensive understanding of 
the trafficking of different immune cell populations 
during EAE, a reliable cell tracking method that 
employs high resolution imaging would be 
advantageous. Over the past decade several 
developments have been made within the MRI field 
that has enabled scientists to track cells in vivo. The 
prospect of being able to non-invasively track immune 
cells in vivo is not only fascinating for scientists 
studying the pathophysiology of inflammation but also 
for clinical researchers administering immune cell 
therapies such as dendritic cell vaccines in the clinic 29.  
Labeling of cells for MRI detection has been 
primarily achieved by incorporating contrast agents 
into the cell (via mechanisms of pinocytosis or 
phagocytosis) or by tagging them to cellular surface 
entities 30,31. The labeling of cells in this manner 
renders them distinguishable from surrounding cells 
by MRI. Such cell labeling strategies make use of 
contrast agents that modulate the nuclear magnetic 
resonance (NMR) relaxation times (T1, T2, T2*) of 
the labeled cells. Shortening of T1 or T2/T2* on these 
sequences results in an increase or decrease in signal, 
respectively. T1 agents include gadolinium (Gd) 
chelates such as Gd-DTPA (diethylene-triamine 
pentaacetic acid) or manganese (Mn) chelates such as 
Mn-DPDP (mangafodipir trisodium). On the other 
hand iron oxide nanoparticles are employed as T2* 
enhancement agents. The latter contrast agents have 
been commonly employed to study immune cell 
infiltration in EAE  21,32–34. A variety of iron oxide–
based labels are available including superparamagnetic 
iron oxide particles (SPIO), ultrasmall iron oxide 
agents (USPIO) and micrometer-sized iron oxide 
particles (MPIO). The latter are particularly applicable 
for the labeling of pathological cells since they are 
practical for long-term experiments 35 and are also 
taken up rapidly and without any adverse effects by 
these cells 36. SPIO T2* contrast agents have been 
employed for labeling various cells including 
macrophages 37 and oligodendrocyte progenitors 38 and 
clinical SPIO have been approved by the FDA to label 
dendritic cells that are applied as cancer vaccines in 
melanoma patients 39.  
One drawback of contrast agents that modulate the 
NMR relaxation times is a general difficulty to 
distinguish negative contrast created by contrast-
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labeled cells from other susceptibility-related T2* effects 
such as paramagnetic deoxygenated blood (blood clots or 
air bubbles) 40. Furthermore, the background signal from 
flowing water makes it difficult to identify labeled 
cells/tissue especially if the approximate localization is not 
known a priori.  
These problems are overcome with the application of 
fluorine (19F)-rich nanoparticles since it is possible to track 
cells labeled with these particles very selectively in vivo 41. 
Fluorine is distinct from any other NMR-active atom; its 
negligible endogenous presence in the body provides 
essentially a 19F background free signal. One other 
advantage of 19F MRI is the possibility to overlay cells 
labeled with 19F-nanoparticles with the anatomic proton 
(1H) image (1H MRI). Thus 19F-MRI provides an important 
counterpart to 1H-MRI. The potential applications for 19F-
rich compounds in magnetic resonance spectroscopy 
(MRS) and MRI have long been recognized 42,44. Fluorine 
compounds that are commonly used in biomedical 
applications are chemically inert and synthetically derived 
perfluorocarbons (PFCs) that consist primarily of carbon 
and fluorine atoms. These fluorine-rich compounds are 
insoluble in water and must therefore be emulsified for 
clinically relevant applications such as intravenous, 
intraperitoneal or intraparenchymal injections. The 
particles obtained by emulsification typically have a size 
of approximately 200 nm. The size of the PFC particles 
employed in recent studies to label cells for in vivo 19F-
MRI tracking ranged from 100 nm to 230 nm 41,45,47. We 
have recently shown that the efficiency in labeling 
dendritic cells with perfluoro-15-crown-5-ether (PFCE) 
particles – as shown from the 19F spectral signal – 
increases with increasing particle size (560>365>245>130 
nm) 48.  
 
Increasing evidence suggests that the physico-chemical 
properties of nanoparticles could modulate the immune 
system 49. In our study we could show that the larger 
fluorine-rich particles (560 nm) promote the maturation of 
DC and as a result the priming of naïve T cells 48. A 
previous report on the physical properties of nanoparticles 
also demonstrated a skewing of the T cell response: 
particles larger than 1 μm induced a Th1 response in vivo, 
whereas particles smaller than 500 nm were associated 
with a Th2 response 50. In contrast to smaller particles, 
larger particles (>500 nm) alter DC biology by 
precipitating different uptake mechanisms. Particles larger 
than 500 nm are commonly taken up by phagocytosis, in 
contrast to particles smaller than 500 nm that are usually 
taken up by endocytosis via structures such as caveolae or 
clathrin-coated vesicles. However, apart from particle size, 
it is possible that other biologically-relevant changes in 
particle characteristics – such as shape and surface 
topology – could also alter DC biology. Scientists are 
indeed studying such parameters to deliver solutions for 
controlling biological responses 52. It would therefore 
be interesting to study the influence of other physical 
parameters on DC immunogenicity. Such studies are 
important to perform in preclinical studies since any 
undesirable modulation of the transplanted immune 
cells might pose potential hazards in certain clinical 
settings especially in those where the immune 
response should be kept under control e.g. in 
autoimmune disease and transplantation medicine.  
 
In summary, the visualization of lesion development 
by in vivo µMRI and cell tracking by 19F-MRI 
provides an opportunity to closely follow the 
autoimmune process throughout disease progression in 
the EAE. Thus, in parallel to conventional histological 
examination and in combination with other contrast 
agents, µMRI and 19F-MRI will be invaluable tools for 
longitudinal studies investigating immune cell 
infiltration during brain inflammation and for the 
evaluation of novel therapeutic strategies for MS. 
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